Analysts have been eager to weigh in on the Healthcare sector with new ratings on Apellis Pharmaceuticals (APLS – Research Report), Quest Diagnostics (DGX – Research Report) and Healthcare Services (HCSG – Research Report).
Apellis Pharmaceuticals (APLS)
Robert W. Baird analyst Colleen M. Kusy maintained a Buy rating on Apellis Pharmaceuticals on April 24 and set a price target of $100.00. The company’s shares closed last Thursday at $47.93.
According to TipRanks.com, Kusy has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Apellis Pharmaceuticals with a $83.23 average price target, which is a 68.9% upside from current levels. In a report issued on April 9, Needham also maintained a Buy rating on the stock with a $85.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Quest Diagnostics (DGX)
Robert W. Baird analyst Eric Coldwell maintained a Hold rating on Quest Diagnostics on April 23 and set a price target of $138.00.
According to TipRanks.com, Coldwell is a 4-star analyst with an average return of
Quest Diagnostics has an analyst consensus of Hold, with a price target consensus of $145.45, which is a 5.7% upside from current levels. In a report issued on April 16, Barclays also maintained a Hold rating on the stock with a $138.00 price target.
Healthcare Services (HCSG)
Robert W. Baird analyst Andrew Wittmann maintained a Hold rating on Healthcare Services on April 24 and set a price target of $13.00. The company’s shares closed last Thursday at $11.00.
According to TipRanks.com, Wittmann is a 5-star analyst with an average return of
Currently, the analyst consensus on Healthcare Services is a Moderate Buy with an average price target of $14.50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on APLS:
- Apellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financial Results
- Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Apellis Pharmaceuticals to Host a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
- Apellis appoints Philip Ferrone as chief medical retina advisor
- Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor
